Subscribe To

Price Alert Latest News Economic Calendar News

BLRX / Assessing BioLineRx As A Buy After Drug Approval

BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patients, with a high success rate in optimal stem cell collection. However, there are concerns about competition from generic versions of a similar drug and the decreasing need for immediate autologous transplants in patients with multiple myeloma. Read More

Demo Live Account See Partner Details

Content Topics

Assessing

Biolinerx

After

Drug

Approval

Stock

BLRX

Posted: Sep 18 2023, 01:28

Author Name: Seeking Alpha

BLRX News

By InvestorPlace
October 30, 2023

3 Top Penny Stocks to Make You a Millionaire in 5 Years

In general, penny stock investing is all about quick gains. Investors in this high-risk world usually are in it for a quick buck.

By Seeking Alpha
September 18, 2023

Assessing BioLineRx As A Buy After Drug Approval

BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impr

By Proactive Investors
September 11, 2023

BioLineRx rallies on FDA approval of Aphexda with Filgrastim

Bioline RX Ltd (NASDAQ:BLRX) shares jumped at the market open on Monday after the US Food and Drug Administration approved the use of Aphexda (motixa

By InvestorPlace
July 18, 2023

3 Smart Penny Stocks with Huge Potential

When it comes to investing in top penny stocks, a word of caution. Do your due diligence before buying.

By Seeking Alpha
July 10, 2023

BioLineRx: PDUFA Catalyst And PDAC Advancement Make This Worth A Look

A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a

By InvestorPlace
June 29, 2023

The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023

Now is a great time to accumulate top undervalued biotech stocks. For one, the sector is recession-proof.

By InvestorPlace
April 4, 2023

The 3 Best Biotech Stocks Under $1 to Buy for April

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech st

By Seeking Alpha
March 22, 2023

BioLineRx Ltd. (BLRX) Q4 2022 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2022 Earnings Conference Call March 22, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.